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Myo-inositol (MI) is involved in several important aspects of cell physiology including cell signaling and the control of intracellular osmolarity
i.e. by serving as a “compatible osmolyte”. Currently, three MI cotransporters have been identified: two are Na+-dependent (SMIT1 and SMIT2)
and one is H+-dependent (HMIT) and predominantly expressed in the brain. The goal of this study was to characterize the expression of SMIT2 in
rabbit kidney and to compare it to SMIT1. First, we quantified mRNA levels for both transporters using quantitative real-time PCR and found that
SMIT1 was predominantly expressed in the medulla while SMIT2 was mainly in the cortex. This distribution of SMIT2 was confirmed on
Western blots where an antibody raised against a SMIT2 epitope specifically detected a 75 kDa protein in both tissues. Characterization of MI
transport in brush-border membrane vesicles (BBMV), in the presence of D-chiro-inositol and L-fucose to separately identify SMIT1 and SMIT2
activities, showed that only SMIT2 is expressed at the luminal side of proximal convoluted tubules. We thus conclude that, in the rabbit kidney,
SMIT2 is predominantly expressed in the cortex where it is probably responsible for the apical transport of MI into the proximal tubule.
© 2007 Elsevier B.V. All rights reserved.Keywords: Myo-inositol transport; Membrane transport; SMIT2; Rabbit renal BBMV1. Introduction
Myo-inositol (MI), a cyclic polyol, is the most biologically
abundant stereo-isomer of the inositols which serve as pre-
cursors to molecules involved in cell signaling via the inositol
phosphate pathways [1,2]. MI is also used as a “compatible
osmolyte” allowing renal cells, amongst others, to function
under hypertonic conditions [3]. TheMI plasma concentration is
approximately 50 μM and originates from both dietary intake
and synthesis from glucose [4]. Its metabolism is highest within
the kidney [3,5] where most of the MI transported at the apical
membrane is oxidatively cleaved to yield D-glucuronic acid in
proximal tubule cells. Cellular concentrations ofMI can reach up⁎ Corresponding author. Groupe d’Étude des Protéines Membranaires
(GÉPROM), Université de Montréal, C.P. 6128, Succ. Centre-Ville, Montréal,
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doi:10.1016/j.bbamem.2007.01.007to 30 mM, relying essentially on the activity of secondary active
cotransporters [6]. To date, three MI transporters have been
identified: two are Na+-dependent, SMIT1 and SMIT2, while
the third is H+-dependent and is called HMIT.
SMIT1 was first isolated from Madin–Darby canine kidney
(MDCK) cells using expression cloning in Xenopus oocytes [7].
In rats, mRNA encoding this transporter has been detected in
kidney medulla, cortex, and brain using Northern blot analysis
[7]. In situ hybridization showed that SMIT1 is predominantly
present in the medullary and cortical thick ascending limb (TAL)
and, to a lesser extent, in the inner medullary-collecting duct
(IMCD) [8]. Mice in which SMIT1 was genetically removed
demonstrated the critical importance of MI transporter during
development as the mice died soon after birth due to respiratory
failure, although neonatal lethality could be prevented by
prenatal maternal MI supplement [9,10]. Altered transport and
metabolism of MI are associated with several pathological
conditions including Down’s syndrome, Alzheimer’s disease
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obsessive compulsive disorder and manic depression, for which
clinical trials based on inositol treatments are being pursued.
A second Na+-MI transporter, SMIT2, has an apparent Km
of 120 μM based on measurements in oocytes expressing the
protein [12]. In human tissues, SMIT2 was shown to be highly
expressed in kidney, heart, skeletal muscle, liver and placenta
with weak expression in the brain [13] while in rabbit, Hitomi
and Tsukagoshi [14] showed that rat SMIT2 is expressed only in
kidney and brain. SMIT2 transports D-chiro-inositol (DCI)
equally well as MI but does not transport L-fucose, while
SMIT1 transports L-fucose but not DCI [12,15]. When
heterologously expressed in the MDCK renal cell line, SMIT2
is clearly targeted to the apical domain [16]. The third MI
transporter, HMIT, is H+-dependent and is predominantly
expressed in the brain but very weakly elsewhere [17,18].
Only one study of MI transport in renal BBM has been
published, more than 25 years ago [19] and it concluded that MI
is transported via a sodium-coupled transporter. Transport was
characterized with an apparent Km of 94 μM and the uptake
was inhibited by D-glucose. No functional assessment of
individual MI cotransporters in kidney has yet been published.
The goal of the present study is to characterize the expression
of SMIT2 in rabbit kidney and to compare it to SMIT1. We
show that SMIT1 is predominantly found in the renal medulla
whereas SMIT2 is present in much greater amount in renal
cortex. Analysis showed that SMIT2 is present both in kidney
cortex and medulla, and is specifically enriched in BBMV.
Functionality studies using purified BBMVextend earlier work
and establish that SMIT2 is responsible for MI transport
through the apical membrane.
2. Materials and methods
2.1. Materials
Radiolabelled 3H-myo-inositol was purchased from Perkin Elmer (Boston,
MA, USA) and nitrocellulose filters for uptake assays were from Millipore
(Billerica, MA, USA). Trizol reagent and DNA primers for quantitative real time
PCR (q-RT-PCR) were purchased from Invitrogen (Carlsbad, CA, USA) and
PNGase F enzyme was obtained from New England BioLabs (Ipswich, MA,
USA). Routine biochemicals were purchased either from Fisher Scientific
(Ottawa, ON, Canada) or Sigma (Oakville, ON, Canada). Rabbits (New Zealand
white male) weighing about 2 kg were provided by Charles River’s Laboratories
(St-Constant, QC, Canada). All animal experimentations were performed in
accordance with the Canadian guidelines and with the Ethics Committee of the
Université de Montréal.
2.2. Kidney Brush-border membrane vesicles isolation and MI
transport procedure
Rabbit kidneys were excised, the capsules were removed and the outer
cortex manually separated from the medulla using a scalpel. Brush border
membrane vesicles (BBMV) were prepared using the magnesium precipitation
technique [16] from fresh renal cortex only, since preparations made from frozen
tissue exhibited a significantly decreased rate of MI transport. The intravesicular
composition was 400 mM mannitol, 0.1 mMMgSO4, 50 mM HEPES–Tris, pH
7. BBMV were either used immediately or frozen in liquid nitrogen until use.
Transport media (150 mM NaCl, 100 mM mannitol or L-fucose, 0.1 mM
MgSO4 and 50 mM HEPES–Tris pH 7) contained tracer quantities of 3H MI
(specific activity 685 GBq/mmol) along with 50 nM cold substrate, unlessotherwise specified in legends. L-fucose DCI, and alpha-methyl-D-glucose (αMG)
were added to the transport media as equimolar replacements for mannitol.
Transport of 3Hmyo-inositol by renal BBMVwas initiated by the addition of 50 μl
BBMV to 950 μl transport medium at room temperature and, at given times,
aliquots of 100 μl were filtered onto 0.65 μm nitrocellulose filters and immediately
rinsed with 5 ml ice-cold substrate-free transport media. Filters were dissolved in
scintillation cocktail (BetaBlend, ICN Biochemicals Inc., CA, USA) and tritium
activity measured using a Beckman LS6000SC scintillation counter.
2.3. Quantitative-real-time PCR
Quantification of both SMIT1 and SMIT2 mRNA was performed using
LUX technology along with the SuperScript™ III Platinum® one-step qRT-PCR
System kit (Invitrogen). Total RNA was isolated from rabbit renal cortex and
medulla using Trizol reagent (Life Technologies, Invitrogen). Primers and
probes were designed using Primer software for LUX technology (https://orf.
invitrogen.com/lux/). Quantifications were performed on 0.5 μg total RNA
samples using the DNA Engine Opticon 2 PCR apparatus (MJ Research Inc,
Walthman, MA, USA). Standards consisted of pure in vitro transcribed mRNA
for either SMIT1 or SMIT2. The qRT-PCR protocol was: 50 °C (30 min) for
reverse transcription, then 95 °C (2 min) followed by 50 cycles at 95 °C (15 sec)
and 59 °C (30 sec). All reactions were run in triplicates and the quality of the
PCR procedure monitored through melting curve analysis. The abundance of the
target mRNAs was calculated according to a standard mRNA curve for both
SMIT1 and SMIT2. Since the rabbit SMIT1 sequence is still unknown, primer’s
sequences were chosen from conserved regions in the SMIT1 sequences from
other known species (rat, human and mouse). Primers used for SMIT1 were:
CGG CTG AGT GGA TAC TTC CTG GCG (forward) and TCA CAA ACA
GAG AGG CAC CAA T (reverse). For SMIT2, the primers sequences used
were: CGC CGA CTG CTG AAT AAA GAT GGG (forward) and ATC ACC
CTG GCC GTC CTC TAC (reverse).
2.4. Antibody production and Western blots
An anti-SMIT2 antibody was raised in rabbits (Biotechnology Research
Institute, Montreal, QC, Canada; http://www.irb.cnrc.gc.ca) against a conserved
amino acid sequence from the SMIT2 protein of rabbit, rat and human aligned
using ClustalW software. The epitope contained 16 amino acid residues
(FLALASNRSENSSCGL; amino acids 238 to 253 localized in the predicted
intracellular loop between the predicted fifth and the sixth transmembrane
domains. Care was taken to avoid sequence regions containing significant
similarities to sequences of related transporters such as SMIT1 or to any SGLT
sequences. The crude serum was tested on rabbit renal cortex, medulla and
purified BBMV. The pre-immune serum was used as a negative control, and the
specificity of the crude serum checked by peptide displacement assay.
Western blots were performed as described [16]. Briefly, samples were
electrophoresed on a 7.5% polyacrylamide gel and transferred onto nitrocellu-
lose membranes. The efficiency of the overall procedure was monitored by
Ponceau red staining. The membranes were blocked with 5% non-fat milk in
TBS-T (TBS+Tween 20, 0.1%), probed with the specific antibody at 1/500
dilution followed by probing with an HRP-linked goat anti-rabbit secondary
antibody (Santa Cruz Biotech, CA) at 1/5000 dilution. All incubations with
antibodies were performed in TBS-T with milk. Membranes were rinsed
adequately between every step with TBS-T and revealed using enhanced
chemiluminescence detection (Super-Signal®, Pierce, Canada).
2.5. PNGase assay
N-glycosylation was assayed using the PNGase F enzyme. Rabbit renal
BBMV were subjected to PNGase treatment according to the manufacturer’s
procedure. The reaction mix was incubated for 3 h (or overnight) and proteins
analyzed by Western blot as described above.
2.6. Statistical analysis
Values shown for transport studies represent means±SE of triplicates and are
expressed in nanomoles per mg protein. Protein content was determined using
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was performed by fitting data to the Michaelis–Menten equation containing a
non-specific component of uptake using Origin 6.1 software (OriginLab Corp.,
Northampton, MA, USA). Evaluation of the Ki value for DCI was performed
using a competitive inhibition equation containing a non-specific component of
uptake [20], also using Origin software. All uptake experiments, quantitative
real-time PCR and Western blot analysis were performed on at least three
separate occasions with comparable results. Data presented are from representa-
tive sets of experiments.Fig. 2. Identification of SMIT2 protein in rabbit renal tissues using Western blot
detection. SDS-PAGE and transfer on nitrocellulose were performed as described
in Materials and methods. Membranes were blotted either against pre-immune
sera or against anti-SMIT2 antibody (both at 1/500) either with (peptide) or
without (immune) pre-adsorption to specific SMIT2 peptide on rabbit tissues:
purified rabbit brush-border membrane vesicles (BBMV) (lane 1, 2 μg protein
per lane), kidney homogenates (100 μg per lane) from cortex (lane 2) or medulla
(lane 3). A 75-kDa specific band is detected. The right hand panel shows the
evaluation of SMIT2 N-glycosylation in purified BBMV. Homogenates (2 μg
protein per lane) were treated (+) or not (−) with PNGase for 3 h prior Western
blot analysis. In both cases, a similar 75 kDa protein is detected.3. Results
3.1. Quantitative real-time PCR
In a first attempt to evaluate the relative levels of both
SMIT1 and SMIT2, we quantified specific mRNA levels
through qRT-PCR for both transporters SMIT1 and SMIT2 in
total RNA extracted from renal cortex and medulla. As shown
in Fig. 1, SMIT1 is predominantly found in the medulla (2.9±
0.7×103 copies/μg total RNAvs. 0.8±0.04×103 copies/μg total
RNA in cortex) whereas SMIT2 is present in greater amounts in
cortex (5.1±0.8×103 copies/μg total RNA vs. 0.8± 0.2×103
copies/μg total RNA) than in medulla.
3.2. Western blot analysis
In order to establish the renal distribution of SMIT1 and
SMIT2 at the protein level, tissues from cortex and from
medulla were studied using specific antibodies against SMIT2.
In rabbit kidney tissues (Fig. 2), the antibody reveals a specific
75 kDa band in both cortex and medulla, one which appears to
be highly enriched in BBMV. As shown in Fig. 2, we noticed
that fainter bands with reduced molecular weight (MW) canFig. 1. Quantitative RT-PCR (qRT-PCR) determination of mRNA for SMIT1
and SMIT2 transporters. qRT-PCR was performed using primers that are
specific for SMIT1 or SMIT2 (see Materials and methods) using 0.5 μg total
RNA as template. Absolute quantification (molecules/μg total RNA) is made
possible by interpolation of standard curves for both mRNA using pure cRNA
for both species. Bars are mean±SEM from three independent experiments,
each performed in triplicates.occasionally be observed. This presumably represents some
degradation products of SMIT2. As shown in this figure, all of
the specific signals seen in the presence of the anti-SMIT2
antibody (immune) are absent when treated with the pre-
immune serum fraction and are displaced by peptide preadsorp-
tion of antibody. PNGase F treatment was also performed in
order to test the possibility that the 75 kDa protein is a
glycosylated protein. As seen in Fig. 2, assays performed on
purified BBMV show no reduction of MW, indicating that
SMIT2 is not N-glycosylated in these tissues. Even after 16 h
incubation in the presence of PNGase F, no alterations in MW
were detected (not shown).
3.3. MI transport in purified BBMV
Although an MI transport system(s) in renal BBMV has
already been reported [16], the molecular identity of the
transporter(s) involved has not yet been determined. The
activity of SMIT1 can be distinguished from the activity of
SMIT2 by using L-fucose which is specifically transported by
SMIT1 and DCI which is specifically transported by SMIT2.
Fig. 3 illustrates the uptake of 3H-MI (in the presence of 50 nM
unlabelled MI) into renal BBMV as a function of time, either
alone or in the presence of a saturating concentration of either
DCI (1 mM) or L-fucose (100 mM) to selectively inhibit SMIT2
and SMIT1 respectively, or in the presence of saturating
unlabelled MI to inhibit all MI-specific transport systems. Total
MI transport (●) displayed linearity for 2–3 min and the uptake
curve demonstrates a typical overshoot indicative of secondary
active transport systems (Na+ dependent, in this case). In the
presence of 100 mM L-fucose (▪), the specific rate of
radiolabelled MI transport is reduced by 35% while in presence
of a saturating concentration of MI (△), the uptake is reduced to
80%. When the transport assay is performed in the presence of
1 mM DCI (▴), MI uptake is also reduced by 80%.
Fig. 3. Time course of MI transport into rabbit BBMV. Rabbit BBMV (50 μl)
were incubated with 950 μl transport media containing 50 nM MI along tracer
(see Materials and methods for composition of transport media). Uptakes were
performed either in absence (●) or presence of saturating L-fucose (100 mM,▪),
MI (1 mM, △) or DCI (1 mM, ▴). Addition of L-fucose was performed in
equimolar replacement with mannitol. Aliquots of 100 μl were taken for each
sample. Data are mean±SEM of triplicates. When not shown, error bars are
smaller than symbol.
Fig. 5. Determination of kinetic parameters for MI transport in renal rabbit
BBMV. 2 min uptakes were performed with increasing concentrations of MI
(up to 1 mM). Aliquots of 100 μl were taken for each sample. Data are mean±
SEM of triplicates. When not shown, error bars are smaller than symbol. Inset
presents Eadie–Hofstee transformation of total uptake to which was subtracted
non-specific fraction (Kd component). Kinetic parameters determined were
221±26 nmol×mg protein−1×2 min−1 for Vmax, 57±14 μM for Km and
0.92±0.03 nmol/mg protein−1×2 min−1 for the non-specific Kd value.
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with respect to the overall profile of MI transport, the partial
inhibition induced by L-fucose was somewhat inconsistent with
the similar uptake levels seen in the presence of DCI andMI. We
thus further investigated the inhibitory profile of MI transport on
BBMV by using increasing concentrations of L-fucose, DCI or
MI. As shown in Fig. 4, bothMI and DCI induced a considerable
inhibition of radiolabelled MI uptake with comparable efficien-
cies. On the other hand, L-fucose still only partially impeded the
uptake of MI (38% reduction at 100 mM). This inhibition was
however incompatible with a competitive effect displaying a Ki
of 4.7±1.0 mM as is seen with MDCK cells [16]. L-chiro-Fig. 4. Initial rate of MI transport in absence or presence of potential inhibitors, α-met
(2 min) of 50 nMMI by various effectors on rabbit BBMV were performed as describ
▴), DCI (up to 1mM,△), L-chiro-inositol (1 mM,□), L-fucose (up to 100mM,●) and
bars are smaller than symbol.inositol (LCI, 1 mM), a non-inhibitory stereo-isomer of DCI,
showed no significant inhibition of MI transport, as α-methyl-
glucose (αMG, 1 mM), specific substrate of the Na+/glucose
transporter SGLT1. This indicates that these compounds do not
interfere with the BBMV MI transport.
Fig. 5 shows a typical example of MI transport measurements
at different MI concentrations, performed in the absence of
L-fucose. The data were analysedwith an equation representing a
single site+passive diffusion. The kinetic parameters deter-
mined for the saturable component were 57±14 μM for Km and
221±24 nmol/mg protein−1 ×2 min−1 for Vmax. Transposition
of the saturable portion of the uptake experiment as Eadie–hyl-glucose or L-fucose, DCI, LCI, or MI. Inhibition studies of initial rate uptakes
ed in this figure and Materials and methods. Inhibitors used were αMG (10 mM,
MI (up to 1 mM,▪). Data are mean±SEM of triplicates.When not shown, error
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parameters and equation for competitive inhibition [21], we were
able to determine a Ki value of 63±17 μM for DCI inhibition of
MI uptake for the data presented in Fig. 4.
4. Discussion
To date, three MI transport systems have been identified;
SMIT1, SMIT2 and HMIT, but their individual physiological
functions have not yet been well delineated. For this reason,
this study aimed to examine the relative contributions of
SMIT1 and SMIT2 to MI transport in the rabbit kidney.
Although HMIT was shown to be weakly expressed in the rat
kidney, its involvement in MI transport through rabbit renal
BBMV can be ruled out since the uptake observed is totally
Na+-dependent [19] while HMIT transports MI in a H+-
dependent manner and is largely inefficient at neutral pH
levels (≥7.0) [17,18]. In the present study, using qRT-PCR
evaluation, we demonstrated the presence of both SMIT1 and
SMIT2 in rabbit kidney, and found that they exist in different
proportions in cortex vs. medulla. These are the first
quantitative data concerning renal expression of the SMIT
proteins and they are in agreement with Northern blot analysis
previously published for rabbit SMIT2 [14] which determined
that SMIT2 is expressed only in the brain and the kidney,
although the latter was not further investigated for cortex and
medulla subdistribution. In human, also using Northern blot,
Roll et al. [13] have found a broader distribution for SMIT2
expression including heart, skeletal muscle, kidney, liver, and
placenta while weaker expressions were found in brain and
several other tissues. We do not know if the differences
between these results are due to species differences or to
methodology. Unfortunately, these discrepancies were not
discussed in the study [13]. Quantization of mRNA through
qRT-PRC represents an advantage over Northern blots in terms
of evaluating mRNA distribution in tissues. Data on SMIT1
and SMIT2 evaluation by qRT-PCR have not yet been reported
for other species. The fact that SMIT1 and SMIT2 have
different distributions within the kidney, SMIT1 being more
abundant in medulla while SMIT2 mainly being expressed in
cortex, suggests tissue-specific functions for each transporter.
A major difference between these two transporters is their
polarized location within epithelial cells, since SMIT1 is
usually detected at the basolateral membrane while SMIT2 is
rather found at the apical domain of these cells [16]. In a
previous report from our laboratory [16], the characterization
of MI transport in BBMV has shown that the presence of
100 mM L-fucose inhibits MI transport by about 30%
suggesting the presence of some SMIT1 at this membrane.
In the present study, we have performed a more complete
inhibition study using both L-fucose, a specific inhibitor of
SMIT1, and DCI which specifically inhibits SMIT2 in order to
better distinguish the two systems. The results obtained (Fig. 4)
confirmed the partial effect of L-fucose previously reported but
appear to be inconsistent with the total effect of DCI. Indeed, the
partial inhibition by L-fucose suggests the presence of both
SMIT1 and SMIT2 while the complete inhibition achieved withDCI, clearly indicates that only SMIT2 is found in rabbit
BBMV. Unfortunately, no anti-SMIT1 antibodies are presently
available to allow a direct detection of SMIT1 by Western blot
or immunofluorescence. Still, while 1 mM DCI is sufficient to
attain complete MI transport inhibition, 100 mM L-fucose is
necessary to induce partial inhibition, one that has not even
reached statistical significance at 50 mM. Such a linear
inhibition profile is incompatible with the L-fucose-mediated
inhibition of SMIT1 in normal MDCK cells, for which a Ki
value of 4.8±1.0 mM was observed [16]. Instead, the large
concentrations of L-fucose may reduce MI transport indirectly
through an effect on the Na+ electrochemical gradient. The
linear Eadie–Hofstee plot displayed in the insert of Fig. 5,
showing a Km value compatible with that found by Hammer-
man et al. [19], cannot be used to rule out the presence of a
second transport site since both SMIT1 and SMIT2 share
similar Km values. A possible contribution of the Na+/glucose
cotransporter SGLT1 to MI transport in BBMVwas ruled out by
evaluation of MI uptake in the presence of a saturating
concentration of a substrate for SGLT1 (αMG) which is not
recognized by either SMIT1 nor SMIT2 [12,22]. We thus
conclude that the effect of 100 mM L-fucose on MI transport is
indirect and that SMIT2 is the only MI transport system in the
apical membrane of the proximal convoluted tubule cells as
shown by the complete inhibition of MI uptake by DCI. This
conclusion would suggest a cellular model where SMIT1 and
SMIT2 are restricted to the basolateral and apical membranes,
respectively.
In addition to the first anti-SMIT2 antibody previously used
in our laboratory [16], a second SMIT2-specific antibody was
raised, this time against a new epitope. This antibody, used
throughout the present work, recognizes in kidney tissues a
75 kDa band which closely corresponds to the expected MW for
this protein according to the deduced amino acid sequence
(≈74 kDa). The faint lower MW bands seen in all lanes of
Fig. 2 are most probably degradations of this protein and are
not believed to represent specific variants of SMIT2. This
75 kDa band was found to be more abundant in renal cortex
(lane 2) than in renal medulla (lane 3) and was further
enriched in purified BBMV (lane 1). This is in accordance
with the data obtained by qRT-PCR from the same tissues. In
all cases, both these bands were found to be specific as they
are absent when detected with pre-immune serum and are
displaced by preadsorption of antibody with peptide. Since
SMIT2 possesses an N-glycosylation motif, the possibility that
the 75 kDa is a glycosylated form of the protein was
investigated. As shown in Fig. 2, PNGase F treatment
performed on BBMV showed no reduction of MW when
compared to controls. It should be noted that PNGase assays
were also prolonged for up to 16 h in order to confirm this
finding. The absence of glycosylation is not surprising since
proteins which do not contain a signal peptide, as is the case
for SMIT2, are less incline to acquire such residues even
though they have adequate N-glycosylation motif. Also, it is
worth mentioning that the specific 75 kDa band was also
evidenced in other rabbit tissues such as brain and lung (not
shown).
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much higher than that of MI (50 μM), the affinity of SMIT2 for
glucose is remarkably lower (≈40 mM, [12]) than that for MI
(57 μM). Physiologically, under such conditions where the MI
concentration is equivalent to its Kt while the concentration of
glucose is eight times lower than its Kt, MI would be the
predominant substrate for the transporter. Furthermore, since
glucose is efficiently reabsorbed through SGLT proteins along
the proximal tubule, the substrate competition for SMIT2 will
rapidly drop in favour of MI. For these reasons, we believe that
glucose represents only a small hindrance to MI uptake through
SMIT2 along the proximal tubule.
In conclusion, our results reveal that the rabbit kidney
expresses both SMIT1 and SMIT2, but in opposing proportions
in cortex and medulla. SMIT2 is predominantly expressed in the
cortex where it probably serves as the unique MI transporter
across the apical membrane of the proximal tubule. On the other
hand, SMIT2 is also expressed, albeit at a lower level in the
medulla but its specific role remains to be elucidated.
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